Racotumomab

Drug Profile

Racotumomab

Alternative Names: 1E10; 1E10 anti-idiotype vaccine therapy; Anti-idiotype antibody 1E10; Vaxira

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; Elea; Innogene Kalbiotech; Recombio
  • Class Antineoplastics; Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Neuroblastoma
  • No development reported Breast cancer; Colorectal cancer; Malignant melanoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(In children, In infants) in Argentina (Intradermal, Injection)
  • 01 Nov 2016 Phase-II clinical trials in Neuroblastoma (In children, In infants, Second-line therapy or greater) in Argentina (Intradermal) (NCT02998983)
  • 29 Aug 2016 The Center of Molecular Immunology plans a phase II/III trial for Non-small cell lung cancer (Adjuvant therapy) in Cuba (RPCEC00000207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top